What question did this study set out to answer?

To evaluate the distinct molecular mechanisms responsible for anthracycline-induced cardiotoxicity and assess therapeutic strategies developed to mitigate cardiac damage.

March 1, 2003Anti-Cancer Agents in Medicinal Chemistry

Cardiac Toxicity of Antineoplastic Anthracyclines

View Full Paper

Ask AI

Bookmark

Why the study?

What are the mechanisms of anthracycline-induced cardiotoxicity and what strategies can be used to reduce it?

Population

Patients receiving antineoplastic anthracyclines for solid malignancies

Design

Review

Authors

RZRiccardo ZucchiUniversity of Pisa RDRomano DanesiUniversity of Milan

Discussion

Member takes

Implication

May inform cardioprotection choices with anthracyclines; leaves open prospective validation of disaccharidic derivatives in trials.

Key Points

To evaluate the distinct molecular mechanisms responsible for anthracycline-induced cardiotoxicity and assess therapeutic strategies developed to mitigate cardiac damage.
Reviewed cellular and metabolic pathways of anthracycline toxicity, focusing on oxidative stress, calcium/iron homeostasis, and lipid metabolism rather than topoisomerase II inhibition.
Assessed preclinical and clinical interventions, including structural analogs (such as disaccharidic derivatives), liposomal delivery platforms, and the iron chelator dexrazoxane.
Anthracycline cardiotoxicity is driven by free radical production, sarcoplasmic reticulum calcium release, anionic phospholipid binding, and toxic 13-hydroxy metabolites disrupting ion balance.
Most synthetic derivatives have failed to improve the therapeutic index, though disaccharidic derivatives, liposome encapsulation, and dexrazoxane co-administration effectively diminish cardiotoxic injury.

Structured PICO

What are the mechanisms of anthracycline-induced cardiotoxicity and what strategies can be used to reduce it?

Population

Patients receiving antineoplastic anthracyclines for solid malignancies

Intervention

Anthracyclines and cardioprotective strategies (e.g., liposome encapsulation, dexrazoxane, new disaccharidic derivatives)

Outcome

Acute or chronic cardiac toxicitysafety

This review highlights that anthracycline cardiotoxicity involves multiple mechanisms distinct from topoisomerase II inhibition, and outlines current and future strategies for cardioprotection.

Cite This Study

Zucchi et al. (2003) studied this question.

synapsesocial.com/papers/6a70499726a7f98052dccab2 https://doi.org/10.2174/1568011033353434

Topics

Cardio-oncology

View Full Paper

Ask AI

Bookmark

Cardiac Toxicity of Antineoplastic Anthracyclines

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Cardiac Toxicity of Antineoplastic Anthracyclines

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider